Source: FierceBiotechIT

Pulmagen Therapeutics: Pulmagen med passes phase 2 asthma test, seeks partner for late-stage trials

Pulmagen med passes phase 2 asthma test, seeks partner for late-stage trials badams Wed, 12/14/2016 - 04:41

Read full article »
Pulmagen Therapeutics's Competitors | Pulmagen Therapeutics's News | Pulmagen Therapeutics's Financials
Stay up-to-date with the latest news on Pulmagen Therapeutics
Est. Annual Revenue
$100K-5.0M
Est. Employees
250-500
Christopher Philip Ashton's photo - CEO of Pulmagen Therapeutics

CEO

Christopher Philip Ashton

CEO Approval Rating

69/100

Read more
Stay up-to-date with the latest news on Pulmagen Therapeutics